Coherus BioSciences and Junshi Biosciences have introduced LOQTORZI™ (toripalimab-tpzi) as a treatment option for nasopharyngeal carcinoma (NPC).
LOQTORZI is a next-generation anti-PD-1 monoclonal antibody that works by blocking the interaction of PD-L1 with the PD-1 receptor, thereby activating the body's immune response against the cancer cells.
LOQTORZI has demonstrated a statistically significant and clinically meaningful improvement in overall survival is promising news for patients with this condition. Its ability to reduce the risk of death by 37 percent when used in combination with chemotherapy is a significant advancement in the treatment of NPC.
LOQTORZI's approval makes a new standard of care, particularly in combination with chemotherapy, providing hope for improved outcomes and quality of life for individuals living with NPC.
Nasopharyngeal carcinoma (NPC), a form of cancer typically originates in the nasopharynx, the upper part of the throat behind the nose and near the base of the skull. The fact that surgery is rarely a viable option due to the tumour's location makes it even more crucial to have effective non-surgical treatment options.
The approval of LOQTORZI by the FDA is a positive development, especially for patients who have limited treatment options for this aggressive and life-threatening form of cancer.
